6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]
Published on
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington. D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
I5d-16UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June , 2003
Novogen Limited
(Translation of registrants name into English)
140 Wicks Road, North Ryde, NSW, 2113, Australia
(Address of principal executive office)
[Indicate by check mark whether the registrant files or
will file annual reports under cover of Form 20-F or Form
40-F.
Form 20-F v Form 40-F
[Indicate by check mark whether the registrant by furnishing
the information contained in this Form is also thereby
furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of
1934. Yes No
[If Yes is marked, indicate below the file number
assigned to the registrant in connection with Rule 12g3-2
(b):
82- ________________ .1
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned, thereunto
duly authorized.
Novogen Limited
(Registrant)
Date 9 June, 2003 By
*Print the name and title under the signature of the
signing officer.Ronald Lea Erratt
Company secretary
GENERAL INSTRUCTIONS
A. Rule as to Use of Form 6-K.
are required to furnish reports pursuant to Rule l3a-16 or
15d-16 under the Securities Exchange Act of 1934.
B. Information and Document Required to be Furnished.
Subject to General Instruction D herein, an issuer furnishing
a report on this form shall furnish whatever information, not
required to be furnished on Form 40-F or previously furnished.
such issuer (i) makes or is required to make public pursuant
to the law of the jurisdiction of its domicile or in which it
is incorporated or organized, or (ii) files or is required to
file with a stock exchange on which its securities are traded
and which was made public by that exchange, or (iii)
distributes or is required to distribute to its security holders.
SEC 1815 (7-91)
The information required to be furnished pursuant to (i)
(ii) or (iii) above is that which is material with respect
to the issuer and its subsidiaries concerning: changes in
business; changes in management or control;
acquisitions or dispositions of assets; bankruptcy or
receivership; changes in registrants certifying
accountants; the financial
condition and results of operations; material legal
proceedings; changes in securities or in the security for
registered securities; defaults upon senior securities;
material increases or decreases in the amount outstanding
of securities or indebtedness; the results of the
submission of matters to a vote of security holders;
transactions with directors, officers or principal
security holders; the granting of options or payment
of other compensation to directors or officers; and
any other information which the registrant deems of
material importance to security holders.
This report is required to be furnished promptly after
the material contained in the report is made public as
described above. The information and documents furnished
in this report shall not be deemed to be filed for
the purposes of Section I8 of the Act or otherwise
subject to the liabilities of that section.
If a report furnished on this form incorporates by
reference any information not previously filed with
the Commission, such information must be attached as
an exhibit and furnished with the form.
C. Preparation and Filing of Report.
This report shall consist of a cover page, the document
or report furnished by the issuer, and a signature page.
Eight complete copies of each report on this form shall
be deposited with the Commission. At least one complete
copy shall be filed with each United States stock exchange
on which any security of the registrant is listed and
registered under Section 12(b) of the Act. At least
one of the copies deposited with the Commission and
one filed with each such exchange shall be manually
signed. Unsigned copies shall be conformed.
D. Translations of Papers and Documents into English.
Reference is made to Rule 12b-l2(d) [17 CFR 240.l2b-12(d)].
Information required to be furnished pursuant to General
Instruction B in the form of press releases and all
communications or materials distributed directly to
security holders of each class of securities to which
any reporting obligation under Section 13(a) or 15(d)
of the Act relates shall be in the English language.
English versions or adequate summaries in the English
language of such materials may be furnished in lieu of
original English translations.
Notwithstanding General Instruction B, no other documents
or reports, including prospectuses or offering circulars
relating to entirely foreign offerings, need be furnished
unless the issuer otherwise has prepared or caused to
be prepared English translations, English versions or
summaries in English thereof. If no such English
translations.
versions or summary have been prepared, it will be s
ufficient to provide a brief description in English of
any such documents or reports. In no event are copies
of original language documents or reports required to
be furnished.
ASX & MEDIA RELEASE 9 JUNE 2003
NOVOGEN LICENSEE FILES PATENT INFRINGEMENT SUIT AGAINST
ADM AND AMERIFIT
Novogen Limited has been advised that the licensee of
its soy related patents The Solae Company (formally
known as Protein Technologies International Inc.) has
filed a patent infringement suit against Archer Daniel
Midland Company (NYSE: ADM) and Amerifit Nutrition Inc.
The Solae Company is part of an alliance between DuPont
(NYSE:DD) and Bunge Limited (NYSE:BG).
The lawsuit asserts that ADMs Novasoy isoflavone
products and the Estroven health supplement products
marketed by Amerifit infringe certain patent rights
of The Solae Company. Novogens recently granted US
patent which covers the use of certain isoflavones for
the treatment of menopausal symptoms, forms part of the
patent portfolio available to Solae.
Solae is seeking court orders that ADM and Amerifit stop
selling and making the products claimed to infringe the
patents and is seeking damages. The quantum of damages
sought is not specified.
Novogens Managing Director, Christopher Naughton, said
the inclusion of Novogens recently granted US patent
in this action by Solae confirms the commercial utility
of Novogens expanding intellectual property portfolio.
Novogen markets internationally three of its own
proprietary dietary supplements, Promensil for the
treatment of the symptoms of menopause, Rimostil for
the maintenance of bone and cholesterol health in
post-menopausal women and Trinovin for the maintenance
of prostate and urinary health for men.
ISSUED FOR:NOVOGEN LIMITED
LISTINGS: ASX (CODE NRT), NASDAQ (CODE NVGN).
FOR FURTHER INFORMATION: MR CHRISTOPHER NAUGHTON,
MANAGING DIRECTOR, NOVOGEN LIMITED:TEL 612 9878 0088 http://www.novogen.com
ISSUED BY:WESTBROOK COMMUNICATIONS
CONTACT: DAVID REID TEL (02) 9231 0922
OR 0417 217 157